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Background: Subjective symptoms of temporomandibular disorders (TMDs) have rarely been studied by age
group. We aimed to compare self-reported pain intensity, sleeping difficulty, and treatment outcomes of patients
with myofascial TMDs among three age groups.
Methods: The study population included 179 consecutive patients (151 women and 28 men) who underwent
comprehensive clinical examinations at a university-based orofacial pain center. They were classified into myofascial
pain subgroups based on the Research Diagnostic Criteria for Temporomandibular Disorders. They were stratified by
age group: M1, under 20 years; M2, 20–39 years; and M3, 40 years and older. The patients scored their pretreatment
symptoms (first visit) and post-treatment symptoms (last visit) on a form composed of three items that assessed pain
intensity and one item that assessed sleeping difficulty. Their treatment options (i.e., pharmacotherapy, physical therapy,
and orthopedic appliances) and duration were recorded. All variables were compared between sexes in each group
and between the age groups by using the Kruskal–Wallis test, the Mann–Whitney U test, the chi-square test, and
analysis of variance (p < 0.05).
Results: No significant sex differences were found in any age group. Only sleeping difficulty was significantly
different before treatment (p = 0.009). No significant differences were observed in the treatment options or treatment
duration. After treatment, the intensity of jaw/face pain and headache and sleeping difficulty was significantly reduced
in groups M2 and M3, but only the intensity of jaw/face pain was significantly decreased in group M1. The changes in
the scores of pain intensity and sleeping difficulty were not different between the groups.
Conclusions: Pain intensity does not differ by age group, but older patients with myofascial TMDs had greater
sleeping difficulties. However, there were no differences between the age groups in the treatment outcomes.
Clinicians should carefully consider the age-related characteristics of patients with myofascial TMDs when developing
appropriate management strategies.
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Temporomandibular disorders (TMDs) include muscu-
loskeletal and neuromuscular conditions that involve the
masticatory muscles, temporomandibular joint (TMJ), and
associated structures [1]. They are a subclass of muscu-
loskeletal disorders and cause nondental pain in the
orofacial region [1]. TMDs primarily affect young and
middle-aged adults rather than children or the elderly
[2], although symptoms are frequently observable in the
latter populations [3-6]. Most TMDs occur between
20 years and 40 years of age, show a female preponderance
[7,8], and are self-limiting or fluctuate over time [9].
TMDs are associated with many diagnostic features
such as internal derangements and myogenous disorders
[10]. They can be classified according to the extent of
TMJ and muscular involvement. The Research Diagnostic
Criteria for Temporomandibular Disorders (RDC/TMD)
allow standardization and replication of research on the
most common forms of TMDs [11]. Symptoms of TMDs
can accordingly be investigated by diagnostic subgroups.
Patients with chronic TMDs in the myofascial pain sub-
group (i.e., RDC/TMD, Axis I, Group I) reportedly have
greater dysfunctionality, higher pain intensity, and greater
psychological difficulties, compared to patients in the intra-
capsular pain subgroup (i.e., RDC/TMD, Axis I, Group II
or Group III) [12,13]. In addition, young patients with
myofascial pain have significantly greater difficulty in sleep-
ing, compared to patients with TMJ-related problems [14].
Symptoms of joint-related TMDs resolve with minimal
care [15]. However, symptoms of myogenous TMDs can
become chronic because many patients focus less on
tightness in the masticatory muscles or on the presence
of trigger points, which may also be responsible for their
myofascial pain. Patients with chronic myogenous TMDs
may have persistent central sensitization and psychological
comorbidity that is similar to patients with chronic pain
[16]. Therefore, early intervention is needed to reduce
muscle tenderness and associated disability. However, few
studies have compared the subjective symptoms of TMDs
by age group [17-19].
In this study, we aimed to compare self-reported pain
intensity, sleeping difficulty, and treatment outcomes of
patients with myofascial TMDs among three age groups.
We hypothesized that young patients are more likely to
have mild symptoms and their symptoms are easy to
treat, whereas older patients are more likely to show
severe symptoms, which are difficult to treat.
Methods
Study population
We screened 862 consecutive patients who attended the
University of California–San Francisco (UCSF) Center for
Orofacial Pain (San Francisco, CA), a public university-
based specialty clinic that treats TMD and orofacial painproblems. We used a prospective study approach to exam-
ine pretreatment and post-treatment differences in pain
intensity and sleeping difficulty in the three age groups.
We obtained the necessary data from the patients’ medical
records. Ethical considerations were anonymity, privacy,
and obtaining informed consent from all patients. The
UCSF Committee on Human Research approved this pro-
spective outcome study.
Diagnostic procedures
The patients underwent standardized comprehensive
clinical examinations by two examiners who were diplo-
mates of the American Board of Orofacial Pain. The
examinations included provocation testing of the TMJs,
measurements of the mandibular and cervical ranges of
motion, determination of TMJ noise, masticatory and
cervical muscle examination, cranial nerve assessment,
and intraoral examination. Additional diagnostic tests
(i.e., imaging, physical therapy evaluation, and other
medical consultation) were performed, if needed.
The RDC/TMD guidelines were followed for classifi-
cation, based on the primary diagnosis. Patients were
excluded if they had neuropathic pain, generalized pain
(e.g., fibromyalgia), neurovascular headache (e.g., cluster
headache or migraine), or any psychiatric disorder. The
RDC/TMD Axis I, Group I.a (i.e., myofascial pain) or
Group I.b (i.e., myofascial pain with limited opening)
included a painful response to palpation of the following
muscle sites: posterior temporalis, middle temporalis,
anterior temporalis, origin of the masseter, body of the
masseter, insertion of the masseter, posterior mandibu-
lar region, submandibular region, lateral pterygoid area,
and tendon of the temporalis [11]. Patients with clinical
features fulfilling the RDC/TMD Axis I Group I.a or
Group I.b criteria were classified as the myofascial pain
subgroup and were the focus of this study. This myofas-
cial pain subgroup was stratified according to age: under
20 years (group M1; n = 41); 20–39 years (group M2;
n = 62); and 40 years and older (group M3; n = 76).
Symptom measurement
The patients completed a form that assessed their
symptoms at the first visit and at subsequent visits during
the treatment period. In several studies, self-reported
questionnaires focused on the intensity of TMD symp-
toms, headaches, and neck pain and related impact on
activities of daily living [20-22]. Self-reported measures
provide the ‘gold standard’ in assessing pain outcomes,
and commonly used methods of rating pain intensity are
reliable and valid [23]. Thus, the form in our study in-
cluded three items related to pain intensity (jaw/face pain,
headache, and neck pain) and one item related to difficulty
in sleeping. To measure pain intensity and sleeping dif-
ficulty, an 11-point numeric rating scale (NRS), which
Karibe et al. BMC Musculoskeletal Disorders 2014, 15:423 Page 3 of 6
http://www.biomedcentral.com/1471-2474/15/423ranged from 0 to 10, was used in which 0 indicated “no
pain/difficulty” and 10 indicated “the worst pain/difficulty
imaginable” [24]. We used the NRS because it is a well-
understood measure for pain evaluation and it has an
acceptable reliability [25]. The patients scored the items
on the 11-point NRS by circling the number that best
represented their pain intensity and sleeping difficulty. For
each age group, the treatment outcomes were analyzed by
comparing the scores of the first visit (i.e., pretreatment)
and last visit (i.e., post-treatment). To compare the treat-
ment outcomes between the age groups, the changes in
the scores were calculated by the difference between
the post-treatment and pretreatment scores (i.e., post-
treatment score − pretreatment score).
Statistical analysis
For each age group, sex differences were assessed with
the Student t test for age and treatment duration, and by
the Mann–Whitney U test for pain intensity and sleep-
ing difficulty. Analysis of variance (ANOVA) and the
chi-square test were used for analyzing differences in
treatment duration and sex ratio, respectively, between
the age groups. The Kruskal–Wallis test was used to
compare pain intensity and sleeping difficulty by age
group. If a significant difference was found, a pair of var-
iables in the three groups was assessed with the Mann–
Whitney U test. Because three tests were performed,
Bonferroni adjustment was applied with the alpha level
set at p = 0.0167 (i.e., 0.05/3). The Wilcoxon signed-rank
test was used to compare subjective symptoms between
the pretreatment and the post-treatment periods. A
value of p < 0.05 was considered significant. All analyses
were performed by using IBM SPSS Statistics 21 soft-
ware (IBM Japan, Tokyo, Japan).
Results
No age group showed any significant sex differences. In
general, 84.4% (151/179) of the study population included
female patients with a higher proportion in group M3
(88.2%) than in groups M1 (80.5%) or M2 (82.3%). How-
ever, the sex ratio was not significantly different between
the age groups (chi-square test, p = 0.60) (Table 1).
Pretreatment pain intensity was not significantly
different among the age groups (Table 2). However,Table 1 Demographic data of patients with myofascial
TMDs by age group
Variable M1 (n = 41) M2 (n = 62) M3 (n = 76)
Median age (y) 15.5 ± 2.5 29.6 ± 5.9 54.9 ± 10.8
Age range (y) 10 − 19 20 − 39 40 − 84
Female/male ratio 33/8 51/11 67/9
M1 = less than 20 years; M2 = 20–39 years; M3 = 40 years and older.
The data are presented by the mean ± the standard deviation or by the
number of patients.significant differences were observed in sleeping diffi-
culty (Kruskal–Wallis test, p = 0.009). Groups M2 and
M3 had similar sleeping difficulties (Mann–Whitney
U test, p = 0.71), but scored significantly higher than
group M1 (Mann–Whitney U test: M1 vs. M2, p = 0.006;
M1 vs. M3, p = 0.005).
Regarding treatment options, patients in groups M2
and M3 were more likely to receive pharmacotherapy,
compared to patients in group M1 (Table 3). However, no
significant difference in the distribution of various treat-
ments was noted (chi-square test, p = 0.76). The average
treatment durations were 15.8 weeks, 18.7 weeks, and
20.0 weeks in groups M1, M2, and M3, respectively, but
this was not significantly different (ANOVA, p = 0.68).
After treatment, the intensity of jaw/face pain, head-
ache, and sleeping difficulty significantly improved in
groups M2 and M3. However, only the intensity of jaw/
face pain significantly reduced in group M1 (Table 4). The
changes in the scores of pain intensity and sleeping diffi-
culty were not different between the groups (Table 5).
Discussion
This study focused on patients with myofascial TMDs
and compared self-reported symptoms between three
age groups. From the findings of previous studies [5,26],
we hypothesized that young patients are more likely to
have mild symptoms and their symptoms are easy to
treat, whereas older patients are more likely to show
severe symptoms, which are difficult to treat. However,
our present findings did not support this hypothesis:
pretreatment symptoms of myofascial TMDs were simi-
lar in all age groups and no differences were found in
the treatment outcomes among the different age groups.
A study of consecutive patients of all ages showed that
85.4% of patients who sought treatment for TMDs were
females [27], which was consistent with our findings in
each age group (i.e., more than 80%). Therefore, TMDs
show a female preponderance at all ages. Temporoman-
dibular disorder conditions such as myofascial pain are
associated with female sex [28]. Women with TMDs
report more severe physical symptoms, compared to
men [29]. However, ratings of pain rarely show signifi-
cant sex differences [30]. In our study, pain intensity wasTable 2 Comparison of pretreatment symptom scores
between the age groups
Symptom M1 (n = 41) M2 (n = 62) M3 (n = 76) p*
Jaw/face pain 5.5 ± 2.9 5.3 ± 2.4 5.5 ± 2.2 0.83
Headache 4.2 ± 3.3 3.6 ± 2.5 4.2 ± 3.3 0.41
Neck pain 3.2 ± 3.4 3.6 ± 2.7 4.1 ± 3.0 0.26
Sleeping difficulty 2.7 ± 3.2 4.2 ± 3.0 4.5 ± 3.4 0.009
M1 = less than 20 years; M2 = 20–39 years; M3 = 40 years and older.
The data are presented by the mean ± the standard deviation.
*The p value is based on the Kruskal–Wallis test.
Table 3 Treatment options and duration by age group
Treatment M1 (n = 41) M2 (n = 62) M3 (n = 76)
Pharmacotherapy 23 (56.1) 50 (82.0) 52 (83.1)
Physical therapy 25 (61.0) 45 (75.4) 47 (61.0)
Pharmacotherapy + physical therapy 17 (41.5) 38 (62.3) 41 (53.2)
Orthopedic appliances 6 (14.6) 8 (13.1) 7 (9.1)
Outside reference 5 (12.2) 3 (4.9) 9 (11.7)
Duration of treatment (wk) 15.8 ± 10.3 18.7 ± 18.3 20.0 ± 33.2
M1 = less than 20 years; M2 = 20–39 years; M3 = 40 years and older.
The data are presented by the number of patients (%) or by the mean ± the standard deviation.
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have been influenced by the selection bias associated
with the patients’ seeking health care [31].
Levitt and McKinney [29] report that the pain severity
of patients with TMDs is the same across age groups
and that the severity of symptoms is greater in groups in
which TMDs have existed for a long duration. We did
not study the natural course of the disease in the
present study; however, the patients with myofascial
TMDs experienced similar pain intensity, regardless of
age. From our results, the duration of treatment was
not different between the age groups, which suggests a
similar duration of TMDs. Furthermore, each age group
showed a wide range in the standard deviation for each
symptom score, which indicated different levels of
severity in each age group. These factors may have
influenced the lack of a significant difference in pain
intensity associated with myofascial TMDs. However,
even patients younger than 20 years have headache and
neck pain intensity that is similar to that of older
groups. Individuals who develop TMDs are more likely
to describe comorbidities such as headache and otherTable 4 Comparison of pretreatment and post-treatment sym
Symptom M1 (n = 41) p* M2
Jaw/face pain
Before 5.5 ± 2.9
0.002
5.
After 4.1 ± 2.4 3.
Headache
Before 4.2 ± 3.3
0.28
3.
After 3.6 ± 3.0 2.
Neck pain
Before 3.2 ± 3.4
0.88
3.
After 3.1 ± 2.9 3.
Sleeping difficulty
Before 2.7 ± 3.2
0.96
4.
After 2.7 ± 3.1 2.
M1 = less than 20 years; M2 = 20–39 years; M3 = 40 years and older.
The data are presented by the mean ± the standard deviation.
*The p value is based on the Wilcoxon signed-rank test.body pain [32,33]. Clinicians should therefore pay more
attention to young patients with myofascial TMDs who
complain of high-intensity pain.
Myogenous pain is treated by various strategies such as
trigger point injections, vapocoolant spray and stretch,
transcutaneous electrical nerve stimulation, biofeedback,
posture correction, tricyclic antidepressants, muscle relax-
ants and other medications, and by addressing perpetuat-
ing factors [34]. Fricton [34] states that the complexity of
the treatment program needs to match the complexity of
the patient’s condition. In the current study, pharmaco-
therapy was provided by one of two board-certified orofa-
cial pain specialists and included analgesics (nonsteroidal
anti-inflammatory drugs), muscle relaxants (cyclobenzapr-
ine, 10 mg), and low-dose tricyclic antidepressants (ami-
triptyline, 10–25 mg). Physical therapy was provided by a
licensed therapist and included a home-care program (i.e.,
self-management and exercise regimen), posture training,
mobilization, and the use of physical agents such as ultra-
sound or vapocoolant spray. Dental treatment other than
orthopedic appliances (i.e., interocclusal splints) was not
provided to most patients.ptom scores by age group




















8 ± 2.6 3.2 ± 3.0
Table 5 Comparison of the changes in the scores
between age groups
Symptom M1 (n = 41) M2 (n = 62) M3 (n = 76) p*
Jaw/face pain −1.4 ± 2.8 −1.9 ± 2.5 −2.0 ± 3.2 0.53
Headache −0.5 ± 3.1 −1.3 ± 3.1 −1.8 ± 4.3 0.24
Neck pain 0.1 ± 2.4 −0.5 ± 2.7 −0.8 ± 3.9 0.33
Sleeping difficulty −0.1 ± 2.8 −1.5 ± 3.2 −1.2 ± 4.7 0.08
M1 = less than 20 years; M2 = 20–39 years; M3 = 40 years and older.
The data are presented by the mean ± the standard deviation. The score
change is calculated by the difference between the post-treatment and pre-
treatment symptom scores (i.e., score change = post-treatment symptom score
– pretreatment symptom score).
*The p value is based on the Kruskal–Wallis test.
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cantly differ by age group, although medications tended
to be prescribed more frequently in groups M2 and M3.
The average duration of treatment was more varied in
group M3. We did not determine the treatment periods
of each patient because the treatment interval varied
among the age groups. We defined the treatment dur-
ation as the time from the first visit to the last visit. Fur-
ther, older patients may have a chronicity of symptoms
[5]. These factors may have influenced the large disper-
sion of treatment duration in group M3.
A study that compared treatment outcomes of young
patients (20–30 years) and elderly patients (50–70 years)
with TMDs [18] showed that, although 54% and 38% of
the respective groups had a muscle disorder diagnosis,
both groups responded equally well to a conservative
treatment regimen and experienced marked reduction in
pain. In the present study, the patients in all age groups
demonstrated a significant decrease in jaw/face pain
after the treatments, and the changes in the scores were
not different between the age groups. Therefore, conser-
vative treatment methods are effective for myofascial
TMDs at all ages.
Approximately one-third of patients with TMDs report
poor sleep quality [1]. Numerous factors such as medical
condition, mental disorders, breathing disorders during
sleep, or other sleep disorders can induce insomnia symp-
toms [35]. A population-based study reports that insomnia
is one consequence of chronic pain [36]. A recent epi-
demiological study reports that the prevalence of difficulty
in maintaining sleep increased with age, reaching nearly
50% in elderly individuals (i.e., older than 60 years) [37].
Older patients are more likely to have a physical illness—
especially arthritis and heart disease—or have a painful
physical affliction such as back pain. These physical condi-
tions may cause older patients to experience greater sleep-
ing difficulty, compared to young patients. In our study,
groups M2 and M3 had greater pretreatment sleeping dif-
ficulty but had a significant post-treatment improvement.
They also reported a similar level of sleep difficulty as that
of the young patients. A meta-analysis of fibromyalgiashowed that patients treated with cyclobenzaprine were
three times more likely to report moderate reductions in
individual symptoms, particularly in sleep [38]. In the
present study, medications (i.e., muscle relaxants) and a
home-care program (i.e., sleeping position and using
appropriate pillows) may have improved self-reported
sleep difficulty in the older patients.
We did not assess treatment effectiveness. Because of
this limitation, we cannot describe the most effective
treatment for symptoms of myofascial TMDs in young
or elderly patients. However, tailored treatment proto-
cols are necessary for patients with TMDs. Further well-
designed studies are needed to clarify the effects of each
treatment and the effects of patient compliance with a
home-care program on reducing orofacial pain and diffi-
culty in sleeping.
Conclusions
Pain intensity associated with myofascial TMDs does not
differ by age, but older patients experience greater sleeping
difficulty, compared to young patients. Conservative treat-
ment strategies can reduce pain in the jaw or face region at
all ages. Treatment outcomes of self-reported pain intensity
and sleeping difficulty are not different between different
age groups. Clinicians should carefully consider the age-
related characteristics of patients with myofascial TMDs
when developing appropriate management strategies.
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